Overview of Arthotec

Quick Facts

Property	Description
Active Ingredients	Diclofenac Sodium and Misoprostol
Form	Oral Tablet (Delayed-Release Combination)
Pharmacological Class	NSAID and Prostaglandin Analog Combination
Common Type	Anti-inflammatory and Gastric Mucosal Protective Agent
Origin	Synthetic

Defining Arthotec: A Fixed-Dose Combination Medicine

Arthotec, known by its generic name Diclofenac Sodium and Misoprostol, is a prescription-only medicine administered via the oral route as a tablet. This product is a Fixed-Dose Combination that integrates two distinct active ingredients for complementary therapeutic purposes. It is classified as an NSAID and Prostaglandin Analog Combination, a structure clinically recognized for providing effective pain management while simultaneously mitigating the likelihood of specific gastrointestinal complications. This unique synthetic composition is intended for adult patients who require sustained anti-inflammatory therapy.

Composition and Dual Pharmacological Class

The medicine contains Diclofenac Sodium, which serves as the potent Nonsteroidal Anti-inflammatory Drug (NSAID) component, and Misoprostol, which is categorized as a Prostaglandin E1 Analog. The tablet is specially engineered with a delayed-release mechanism. The Diclofenac component is secured in an enteric-coated core designed to postpone release until the small intestine. Conversely, the Misoprostol is formulated for immediate dissolution from the outer layer. This pharmaceutical design ensures the mucosal protective agent is available locally early in the digestive process.

Therapeutic Purpose and Rationale of the Combination

The general purpose of this combination medicine is to provide relief from pain and stiffness using the powerful anti-inflammatory action of Diclofenac, while concurrently offering gastric mucosal protection with Misoprostol. The Diclofenac acts as an analgesic by inhibiting inflammatory pathways. The Prostaglandin Analog actively replaces protective substances, thereby shielding the stomach and upper intestine lining from the potential irritation caused by the NSAID. This dual pharmacological class design is centered on providing a comprehensive therapeutic approach for chronic conditions where sustained NSAID use is required.

What side effects are possible with Arthotec?

Possible Side Effects and Safety Information

The official regulatory safety profile for this medicine highlights several major, serious risks and classified adverse reactions.

Serious Safety Risks (Boxed Warnings)

Official labeling contains prominent warnings regarding three primary, severe risks:

Serious Gastrointestinal Risk: The medicine may increase the risk of potentially fatal gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time during therapy and may be present without warning symptoms.
Serious Cardiovascular Thrombotic Risk: The NSAID component is associated with an increased risk of serious cardiovascular thrombotic events such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with longer duration of use and is associated with higher doses.
Fetal Toxicity/Contraindication in Pregnancy: Due to the misoprostol component, administration to women who are pregnant can cause fetal harm, including abortion, premature birth, birth defects, or uterine rupture. Therefore, its use is contraindicated in pregnant women.

Classified Adverse Reactions

The adverse reactions documented in clinical trials and post-marketing reports are classified by frequency and system-organ class:

Frequency Category	Examples of System-Organ Classes
Most Common (e.g., ge 2%)	Abdominal pain, diarrhea, dyspepsia, nausea, flatulence, headache, vomiting
Other Classes	Nervous system disorders (e.g., dizziness, insomnia), Skin and subcutaneous tissue disorders (e.g., rash, pruritus), Renal and urinary disorders, Blood and lymphatic system disorders

Serious skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Fixed Drug Eruption (FDE), have been reported rarely and require immediate discontinuation. Other serious reactions include anaphylactic reactions, liver toxicity (hepatotoxicity), kidney toxicity (renal toxicity), and heart failure.

Safety Restrictions and Limitations

The medicine is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Due to the fetal risk, it is also contraindicated in women who are pregnant and not recommended for women of childbearing potential unless effective contraception is used and the patient is advised of the risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Arthrotec is governed by the combined toxicological profiles of Diclofenac and Misoprostol, presenting as an acute exaggeration of documented adverse effects. Clinical manifestations include CNS effects such as headache, confusion, drowsiness, and convulsions, alongside severe gastrointestinal distress like abdominal pain, vomiting (potentially bloody), and profuse diarrhea. Severe exposure is officially documented to be associated with life-threatening outcomes, including acute renal failure, hepatic injury, and massive gastrointestinal perforation or hemorrhage. Cardiovascular events, such as hypotension or stroke, are also documented risks in a severe overdose setting.

Immediate medical attention is mandated for specific severe symptoms, including collapse, the onset of seizures, severe chest pain, trouble breathing, or any signs of bleeding, such as black or tarry stools. No specific antidote is known for this combination medicine. Management is required to be symptomatic and supportive, involving procedural steps such as gastric decontamination with activated charcoal, and close hospital monitoring of vital signs and renal function.

Regulatory warnings note that elderly patients face a greater risk for severe gastrointestinal events. Furthermore, the Misoprostol component carries the specific risk of uterine contractions or rupture in women of childbearing potential.

Therapeutic Uses of Arthotec

Main Uses of Arthotec

Arthotec is a combination medication specifically designed for individuals who require treatment for inflammatory joint conditions but are at high risk of developing gastrointestinal complications. It contains two active components that work simultaneously to manage symptoms and protect the digestive lining.

Inflammatory Conditions

The medication is primarily used to manage the signs and symptoms of two chronic conditions:

Osteoarthritis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone, leading to pain and stiffness.
Rheumatoid Arthritis: An autoimmune disorder where the immune system attacks the joints, causing painful swelling, inflammation, and potential joint deformity.

Therapeutic Benefits

Arthotec provides a dual-action approach to treatment by addressing both the primary symptoms of arthritis and the secondary risks associated with long-term medication use.

Pain and Inflammation Management

One component of the medication is a nonsteroidal anti-inflammatory drug (NSAID). This agent works by reducing the production of substances in the body that cause pain, fever, and inflammation. Patients typically experience a reduction in joint swelling, morning stiffness, and pain during physical activity.

Gastric Protection

The second component is a synthetic prostaglandin. NSAIDs can often deplete the natural protective lining of the stomach, which may lead to the formation of ulcers. This protective element helps to inhibit gastric acid secretion and protects the mucosal lining of the stomach and duodenum. This makes the medication a functional option for patients who have a history of gastric ulcers or those who are otherwise predisposed to NSAID-induced gastric irritation.

Regulatory References

NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Arthotec?

This section outlines the population eligibility rules for Arthrotec (Diclofenac Sodium and Misoprostol), strictly based on governmental regulatory documents.

Eligibility Scope

Category	Official Regulatory Classification
Populations Allowed	Adult patients (18 years and older) who require NSAID therapy and are at high risk of developing NSAID-induced gastric or duodenal ulcers.
Populations Contraindicated	Pregnant women or women planning a pregnancy; Women of childbearing potential not using effective contraception; Patients with known hypersensitivity to aspirin, NSAIDs, or components.
Age-Related Rules	Adults are the approved population; Children/Pediatrics (under 18 years): Safety and efficacy have not been established. Geriatric patients require close monitoring.
Condition-Specific Rules	Severe failure of the heart, kidneys, or liver defines a contraindicated population. Active gastrointestinal bleeding, perforation, and peri-operative pain for CABG surgery are also contraindications. Mild-to-moderate organ impairment requires close monitoring and caution.

Official Eligibility Summary

Regulatory documents strictly define who can and cannot use Arthrotec. The most critical constraint is the absolute contraindication for all women who are or may become pregnant due to the misoprostol component. Furthermore, the medicine is prohibited for individuals with severe cardiac, renal, or hepatic failure, as well as those with aspirin-induced asthma or active GI bleeding. Use is restricted only to adults who meet the high-risk criteria for requiring this fixed-dose combination.

What should I know about interactions with other medicines?

The interaction profile for Diclofenac/Misoprostol (Arthotec) is defined by officially documented patterns that impact pharmacokinetic exposure, reinforce pharmacodynamic risks, and require specific administration restrictions.

Interaction Scope

Medicinal product categories with documented interactions: Anticoagulants, Antiplatelet Agents (including Aspirin), certain Chemotherapy agents (Pemetrexed), Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Diuretics, and CYP2C9 Enzyme Inhibitors or Inducers.

Interaction-related restrictions: Concomitant use with other NSAIDs or salicylates is not generally recommended due to an increased risk of gastrointestinal toxicity. Co-administration with magnesium-containing antacids is not recommended because they reduce the bioavailability of misoprostol acid and may exacerbate diarrhea.

Interaction Classifications (High-Level)

Interaction Severity	Interacting Agents
Synergistic Risk	Anticoagulants (e.g., Warfarin) and SSRIs (increased risk of hemorrhage).
Exposure Alteration	Lithium and Digoxin (can increase serum concentrations).
Metabolic Risk	CYP2C9 inhibitors (may enhance diclofenac exposure) and inducers (may compromise efficacy).

Official interaction statements: Diclofenac may diminish the antihypertensive effect of ACE Inhibitors and ARBs. Co-administration of Pemetrexed requires a mandatory timing restriction for patients with renal impairment (creatinine clearance 45 to 79 mL/min), where Arthotec must be avoided two days before, the day of, and two days following administration of Pemetrexed. The risk of worsening renal function during co-administration with ACE Inhibitors or ARBs is a heightened concern in the elderly.

Mechanism of Action

How Arthrotec Works: A Dual-Action Mechanism

Arthrotec functions through two distinct, complementary mechanistic pathways.

Diclofenac achieves its action through the competitive blocking of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This enzymatic inhibition suppresses the biosynthesis of pro-inflammatory prostaglandins from arachidonic acid. By modulating this key molecular step, diclofenac reduces excessive signaling within inflammatory pathways, resulting in the downstream physiological consequence of lowered prostaglandin levels.

Misoprostol, a synthetic Prostaglandin E1 analog, operates via a second, separate mechanism. It acts as an agonist by binding to and activating specific PGE1 receptors located on gastric mucosal cells. This receptor activation supports the regulation of gastric regulatory processes, including enhanced secretion of mucus and bicarbonate, and modulation of blood flow. This effect adjusts the local prostaglandin levels following the COX inhibition caused by the first component. The drug's mechanism is thus a coordinated action, simultaneously suppressing the systemic inflammatory cascade and supporting the local regulatory feedback of the gastric mucosa.

Dosage and Administration Information

How to Use Arthotec: Official Administration Guidelines

Arthotec is a fixed-dose combination product containing diclofenac sodium and misoprostol, and its usage is strictly guided by the two available tablet strengths: ARTHROTEC 50 (50 mg diclofenac/200 mcg misoprostol) and ARTHROTEC 75 (75 mg diclofenac/200 mcg misoprostol). Administration is exclusively by the oral route.

The fundamental principle of use requires the lowest effective dosage to be taken for the shortest duration consistent with individual treatment goals.

Instruction	Detail
Route of Administration	Oral (by mouth).
Standard Dosing Regimens	One tablet, administered either two, three, or four times daily, depending on the prescribed strength and indication. For example, the regimen for maximal gastric protection is one ARTHROTEC 50 tablet three times daily.
Timing in relation to meals	Tablets should be administered with food to minimize potential gastrointestinal discomfort.
Special Administration	The tablet must be swallowed whole and not be chewed, crushed, or split.
Population Rules	Efficacy has not been established in children (under 18 years). Close monitoring is advised for older adults and patients with hepatic or mild-to-moderate renal impairment.
Maximum Dosage	The maximum recommended total daily dose of diclofenac is 200 mg.

The official instruction protocol mandates a divided, multiple-doses-per-day frequency to ensure the consistent delivery of both active components. By requiring the tablet to be swallowed whole and administered with food, the protocol reinforces the intended sequential release of the gastric protective agent and the anti-inflammatory component.

Recent Clinical Evidence

Evidence for Managing Osteoarthritis and Rheumatoid Arthritis Symptoms

Research examined the use in conditions characterized by fluctuating or episodic manifestations of physical discomfort. Studies exploring this component mainly used Randomized Controlled Trials (RCTs) and double-blind comparative trials, which are used in research exploring how symptoms change over time in adult populations. Studies were applied in research contexts involving fluctuating or unstable symptoms. Researchers monitored patient-reported outcomes describing perceived discomfort and functional limitations, including measures of changes in joint pain, stiffness, and overall patient assessments.

Findings describe patterns observed in the studies where the measurements of pain and stiffness were compared to the diclofenac component administered alone. The research contributes to understanding symptom patterns and how patients reported their experience over defined time intervals. These studies contribute to the broader evidence landscape by exploring short-term symptom patterns in patients who are also evaluated for the gastrointestinal protective component.

Evidence for Preventing NSAID-Induced Ulcers

Research related to the combination product was evaluated in studies exploring the prevention of NSAID-induced gastric and duodenal ulcers. This research primarily relies on endoscopically-guided clinical trials and systematic reviews that specifically examine the anti-ulcer component. Research examined temporary physiological imbalance in patients undergoing anti-inflammatory therapy who were considered at high risk for upper digestive tract complications. Researchers monitored the incidence of endoscopically diagnosed ulcers and the outcomes related to clinical complications such as ulcer bleeding or perforation.

Trial findings indicate patterns associated with a lower measured incidence of ulcers when compared to receiving the anti-inflammatory component alone. The research explored outcomes related to the occurrence of major clinical ulcer complications.

Long-Term Evidence and Study Durations

The duration of the main clinical trials for the symptom relief outcomes was generally short-term to intermediate-term, with many studies observing responses over defined time intervals of 4 to 12 weeks. Follow-up durations were limited across the principal research base for this indication. Observation periods for the anti-ulcer component typically lasted 4 to 12 weeks.

There is limited information for long-term outcomes regarding the maintenance of symptom relief over years of use. Long-term effects are not fully established, and data are still emerging related to the durability of the gastroprotective component when observed over many months.

Research in Special Populations

The primary clinical research for Arthotec was evaluated in adult patients with confirmed osteoarthritis and rheumatoid arthritis. Studies examined patients who were at high risk of developing gastrointestinal damage from nonsteroidal anti-inflammatory drugs (NSAIDs). The results apply only to the specific conditions under which they were conducted, and data for certain groups are still emerging. Research does not determine whether an individual will respond similarly.

Research Gaps and Areas of Uncertainty

Research provides insight into short-term changes and helps show what has been observed so far, but limitations exist. For the symptom management component, follow-up durations were limited to a few months, meaning evidence is limited regarding chronic, long-term outcomes. Research describes that gastrointestinal effects were observed in some studies, leading to patient withdrawal. The patient withdrawal patterns were associated with uncertainty in applying the findings broadly. Comparative evidence is lacking for how this combination was studied against other gastroprotective anti-inflammatory treatments.

Key Studies & References ARTHROTEC (diclofenac sodium and misoprostol) tablets, delayed-release official prescribing information

Frequently Asked Questions (FAQ)

Common questions about Arthotec (FAQ)

Q: How does Arthotec differ from a standard over-the-counter pain reliever?

A: Arthotec is a prescription-only medicine that is a Fixed-Dose Combination product. It contains both an NSAID (diclofenac) and a gastric mucosal protective agent (misoprostol). This combination is typically designated for adult patients who require NSAID therapy but are considered to be at high risk for developing stomach or duodenal ulcers, distinguishing it from most single-ingredient, non-prescription pain relievers.

Q: Can Arthotec cause stomach issues?

A: The medicine is associated with potential gastrointestinal adverse reactions, despite containing a protective component. Official documents indicate that common reactions reported in clinical trials include abdominal pain, diarrhea, nausea, dyspepsia, vomiting, and flatulence. Serious, potentially fatal gastrointestinal issues like bleeding and perforation are also listed as major warnings.

Q: What are the most common side effects listed for Arthotec?

A: According to the official product information, the most common reported adverse reactions are typically related to the digestive system, such as abdominal pain, diarrhea, dyspepsia, nausea, headache, vomiting, and flatulence. Serious adverse reactions, though rare, can also include severe skin reactions and liver or kidney toxicity.

Q: Is Arthotec safe to take with common vitamins?

A: The official product information addresses interactions with medicines and a specific type of supplement. Regulatory documents advise against taking this medicine with magnesium-containing antacids as this may reduce the amount of one component (misoprostol) absorbed. No specific instructions are provided regarding general food or common vitamins.

Q: Does alcohol interact with Arthotec?

A: Official warnings state that using this medicine while drinking alcohol may increase the risk of gastrointestinal bleeding caused by the NSAID component (diclofenac).

Q: Is it safe to drive while taking Arthotec?

A: Official documentation lists nervous system disorders, including dizziness and headache, as reported adverse reactions. The potential for these effects may impact the ability to drive or operate machinery.

Q: Can women who may become pregnant use Arthotec?

A: Arthotec is absolutely contraindicated (prohibited) for women who are pregnant or planning a pregnancy due to the risk of fetal harm. Official guidelines state the medicine is not recommended for women of childbearing potential unless they use effective contraception and are advised of the potential risks associated with use during pregnancy.

Q: Can I take other pain relievers while using Arthotec?

A: Official information advises that the concomitant use (taking at the same time) of Arthotec with other NSAIDs or salicylates (like aspirin) is not generally recommended. This restriction is based on an increased risk of gastrointestinal toxicity.

Q: Why do some people refer to Arthotec as a 'stomach-sparing' NSAID?

A: This descriptive term relates to the drug's design as a fixed combination. The product contains the NSAID (diclofenac) for pain relief, along with misoprostol, a gastric protective agent. The purpose of misoprostol is to help shield the stomach and upper intestine lining from potential irritation caused by the NSAID component.

Q: Is it normal to feel dizzy after starting Arthotec?

A: Dizziness is listed in the official product documents as one of the reported adverse reactions that may affect the nervous system.

Q: Does Arthotec affect blood pressure?

A: Regulatory information advises that nonsteroidal anti-inflammatory drugs (NSAIDs) may cause the new onset or worsening of hypertension (high blood pressure). It is also noted that the NSAID component may diminish the effects of certain medicines prescribed to lower blood pressure.

Q: What foods or supplements interact with Arthotec?

A: The official label advises against taking this medicine with magnesium-containing antacids as this may reduce the absorption of one component. Regulatory information indicates the tablets are administered with food as part of the official use conditions.

Q: Is Arthotec ever prescribed for children?

A: The official product information clearly states that the safety and efficacy of the medicine have not been established in children under 18 years of age. The population approved for the use of this medicine is adult patients.

Q: Does Arthotec contain any opioid ingredients?

A: No. The product is officially defined as a Fixed-Dose Combination of an NSAID (diclofenac sodium) and a Prostaglandin Analog (misoprostol). It does not contain any opioid ingredients.

Q: How quickly is Arthotec eliminated from the body?

A: Pharmacokinetic data in the official prescribing information indicates the diclofenac component has a terminal elimination half-life of approximately 2 hours for the unchanged drug. This information describes how quickly the medicine is processed by the body.

Q: Does Arthotec affect the liver?

A: Yes, serious adverse reactions reported in the official safety profile include liver toxicity (hepatotoxicity). Furthermore, severe failure of the liver also defines a contraindicated (prohibited) population for use of this medicine.

Q: Can people with asthma use Arthotec?

A: The medicine is contraindicated (prohibited) for patients with a history of asthma, urticaria, or other allergic-type reactions that occurred after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).

Q: What is the maximum recommended time frame for using Arthotec?

A: Official guidance mandates that the medicine should be used at the lowest effective dosage for the shortest duration possible. The label also warns that the risk of serious cardiovascular events may increase with a longer duration of use.

Q: Is there a risk of dependence or addiction with Arthotec?

A: The medicine is classified as an NSAID and Prostaglandin Analog Combination. Since it does not contain any controlled or opioid substances, the official warnings do not include risks of dependence or addiction.

Q: What is the official definition of the second component in Arthotec?

A: The second component, Misoprostol, which is included for gastric protection, is officially defined in pharmacological literature as a synthetic Prostaglandin E1 Analog.

How should Arthotec be stored and disposed of?

How to Store and Dispose of Arthotec

Official regulatory guidelines strictly define the necessary storage and disposal methods for Arthotec (diclofenac sodium/misoprostol) to maintain its stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F), commonly known as Controlled Room Temperature.
Protection	Keep the medicine in its original, tightly closed container. Store away from excess heat, moisture, and direct light. Do not freeze.
Safety	Keep the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Arthotec should be disposed of promptly and safely. Do not flush this medicine down the toilet or pour it into a drain unless specifically instructed by a regulatory agency. The official guidance is to follow established drug take-back programs or consult a healthcare professional regarding the proper disposal of unused or outdated medication.

Arthotec